Harris Associates
ABBV icon

Harris Associates’s AbbVie ABBV Stock Holding History

Harris Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$609K Sell
2,420
-262
-10% -$56.4K ﹤0.01% 132
2026
Q1 		$583K Hold
2,682
– – ﹤0.01% 131
2025
Q4 		$613K Sell
2,682
-481
-15% -$110K ﹤0.01% 130
2025
Q3 		$732K Hold
3,163
– – ﹤0.01% 126
2025
Q2 		$587K Buy
+3,163
New +$588K ﹤0.01% 130
2024
Q3 		– Sell
-1,493
Closed -$256K – 147
2024
Q2 		$256K Buy
1,493
+93
+7% +$15.4K ﹤0.01% 128
2024
Q1 		$255K Sell
1,400
-1,400
-50% -$241K ﹤0.01% 130
2023
Q4 		$434K Sell
2,800
-455
-14% -$66.3K ﹤0.01% 130
2023
Q3 		$485K Hold
3,255
– – ﹤0.01% 129
2023
Q2 		$439K Buy
+3,255
New +$477K ﹤0.01% 136
2018
Q3 		– Sell
-22,429
Closed -$2.08M – 124
2018
Q2 		$2.08M Sell
22,429
-18,871
-46% -$1.84M ﹤0.01% 118
2018
Q1 		$3.91M Sell
41,300
-800
-2% -$87.9K 0.01% 119
2017
Q4 		$4.07M Sell
42,100
-18,950
-31% -$1.79M 0.01% 114
2017
Q3 		$5.42M Buy
61,050
+37,350
+158% +$2.84M 0.01% 114
2017
Q2 		$1.72M Buy
+23,700
New +$1.59M ﹤0.01% 112
2015
Q3 		– Sell
-5,759
Closed -$387K – 122
2015
Q2 		$387K Sell
5,759
-32,699
-85% -$2.13M ﹤0.01% 133
2015
Q1 		$2.25M Sell
38,458
-3,963
-9% -$239K ﹤0.01% 125
2014
Q4 		$2.78M Sell
42,421
-36
-0.1% -$2.27K ﹤0.01% 133
2014
Q3 		$2.45M Hold
42,457
– – ﹤0.01% 130
2014
Q2 		$2.4M Sell
42,457
-1,734
-4% -$91K ﹤0.01% 131
2014
Q1 		$2.27M Sell
44,191
-1,865
-4% -$94.3K ﹤0.01% 131
2013
Q4 		$2.43M Hold
46,056
– – ﹤0.01% 134
2013
Q3 		$2.06M Buy
46,056
+497
+1% +$22K ﹤0.01% 135
2013
Q2 		$1.88M Buy
+45,559
New +$1.99M ﹤0.01% 143

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Harris Associates's ABBV Position: Q2 2026 in Review

Harris Associates reduced its AbbVie (ABBV) stake by 9.8% in Q2 2026, selling an estimated $56.4K and leaving 2,420 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #132.

Harris Associates first reported a position in ABBV in Q2 2013 and has held it in 24 quarters since. The position peaked at $5.42M in Q3 2017. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Harris Associates held 2,420 shares of AbbVie worth $609K as of Q2 2026.
  • Harris Associates sold 262 AbbVie shares in Q2 2026, an estimated $56.4K.
  • AbbVie made up ﹤0.01% of Harris Associates's portfolio in Q2 2026, its #132 holding.
  • Harris Associates first reported a position in AbbVie in Q2 2013 and has held it in 24 quarters since.
  • Harris Associates's AbbVie position peaked at $5.42M in Q3 2017.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Harris Associates's 13F filing for Q2 2026, filed 14 Aug 2026.